Fresenius To Buy 51% Of Indonesia Drug Maker For Estimated $200 Million
This article was originally published in PharmAsia News
Fresenius Kabi said it plans to buy a controlling interest in Indonesia's PT Ethica Industri Farmasi in a deal that could be worth as much as $200 million.
You may also be interested in...
The company has no development programs left in its R&D pipeline and will focus entirely on the commercialization of IBS drug Linzess while seeking late-stage assets from external sources.
The documents issued by the US agency on 29 September set slightly different accuracy standards, reflecting the increased fragility of hospital patients.
The US FDA commissioner published a blog post commending and highlighting the work device center staff have done during the pandemic to speed tests and devices to market to save lives.